{"id":252709,"date":"2025-07-10T05:52:09","date_gmt":"2025-07-10T05:52:09","guid":{"rendered":"https:\/\/www.europesays.com\/uk\/252709\/"},"modified":"2025-07-10T05:52:09","modified_gmt":"2025-07-10T05:52:09","slug":"the-uks-apollo-backed-insurance-juggernaut","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/uk\/252709\/","title":{"rendered":"The UK\u2019s Apollo-backed insurance juggernaut"},"content":{"rendered":"<p><strong>One scoop to start: <\/strong>Revolut is in talks to <a href=\"https:\/\/www.ft.com\/content\/f4de3f2e-2476-4048-a035-f1f78a59922e\" data-trackable=\"link\" target=\"_blank\" rel=\"noopener\">raise new funding<\/a> from investors at a $65bn valuation in a transaction that would fuel global expansion for Europe\u2019s most valuable start-up.<\/p>\n<p><strong>And a sibling rivalry scoop: <\/strong>Grant Thornton\u2019s UK and US businesses are <a href=\"https:\/\/ft.com\/content\/39924937-d6f7-4f93-8b0e-0594f9f706f0\" data-trackable=\"link\" target=\"_blank\" rel=\"noopener\">vying to take over<\/a> their German sister firm in a private equity-fuelled race to secure a greater share of the accounting group\u2019s global network.<\/p>\n<p>Welcome to Due Diligence, your briefing on dealmaking, private equity and corporate finance. This article is an on-site version of the newsletter. Premium subscribers can sign up <a href=\"https:\/\/ep.ft.com\/newsletters\/58db721900eb6f0004d56a23\/subscribe\" data-trackable=\"link\" target=\"_blank\" rel=\"noopener\">here<\/a> to get the newsletter delivered every Tuesday to Friday. Standard subscribers can upgrade to Premium <a href=\"https:\/\/www.ft.com\/manage\/subscription\/change\/713f1e28-0bc5-8261-f1e6-eebab6f7600e?segmentId=5d1c2689-3304-f81f-a9e5-b3e96e93c176\" data-trackable=\"link\" target=\"_blank\" rel=\"noopener\">here<\/a>, or <a href=\"https:\/\/www.ft.com\/newsletters\" data-trackable=\"link\" target=\"_blank\" rel=\"noopener\">explore<\/a> all FT newsletters. Get in touch with us anytime: <a href=\"https:\/\/www.ft.com\/content\/mailto:Due.Diligence@ft.com\" data-trackable=\"link\" target=\"_blank\" rel=\"noopener\">Due.Diligence@ft.com<\/a><\/p>\n<p><strong>In today\u2019s newsletter:<\/strong><\/p>\n<ul class=\"o3-editorial-typography-list-unordered\">\n<li>\n<p>Private capital\u2019s UK insurance push<\/p>\n<\/li>\n<li>\n<p>A patent cliff for Big Pharma<\/p>\n<\/li>\n<li>\n<p>Jane Street\u2019s India problem<\/p>\n<\/li>\n<\/ul>\n<p>Apollo wades deeper into UK insurance<\/p>\n<p>There\u2019s a new <strong>Apollo<\/strong>-backed entrant in the UK pensions market and it promises to <a href=\"https:\/\/www.ft.com\/content\/ab7a5547-8175-438f-b81d-e2aaf5a3fd24\" data-trackable=\"link\" target=\"_blank\" rel=\"noopener\">reshape Europe\u2019s largest retail marketplace<\/a> in the coming decades.<\/p>\n<p>Last week, <strong>Athora<\/strong>, an insurance group created by Apollo in 2018, struck the UK\u2019s largest deal this year, agreeing to buy retirement savings group <strong>Pension Insurance Corporation<\/strong> for \u00a35.7bn.\u00a0<\/p>\n<p>The move plants a big Apollo-esque flag in the UK just as the private capital behemoth reshapes the US financial system by matching giant lending marketplaces with insurance policies.<\/p>\n<p>And Apollo isn\u2019t alone. America\u2019s private capital groups have been looking across the pond at European insurers with envy for a while. Now they\u2019re expanding quickly.<\/p>\n<p><strong>Brookfield<\/strong>, <strong>KKR <\/strong>and <strong>Carlyle <\/strong>have all started insurance operations in the country or studied acquisitions over the past few years. The FT previously reported that Carlyle and KKR had also <a href=\"https:\/\/www.ft.com\/content\/a4d2867f-0c3d-4e0d-aaba-d11f60af8592\" data-trackable=\"link\" target=\"_blank\" rel=\"noopener\">studied bids<\/a> for PIC.<\/p>\n<p>The UK is a lucrative market for insurers and one that\u2019s ripe for dealmaking.<\/p>\n<p>Employers in the UK are looking to move pensions liabilities off their balance sheets by selling them to insurers. British businesses are forecast to offload a record \u00a370bn of pensions risk this year, according to pensions consultant <strong>WTW<\/strong>.<\/p>\n<p>And there\u2019s much more of that to come: more than a third of the UK\u2019s defined benefit pension schemes, managing more than \u00a31tn of assets, could <a href=\"https:\/\/www.ft.com\/content\/d927ee04-bcba-4d33-b1d3-459aeb66ea89\" data-trackable=\"link\" target=\"_blank\" rel=\"noopener\">afford to hand over their schemes<\/a> to an insurer, according to the <strong>Pension Protection Fund<\/strong>.<\/p>\n<p>Private capital groups have become the US insurance market\u2019s dominant players, but Europe\u2019s sceptical regulators make it harder to crack.<\/p>\n<p>For the continent\u2019s watchdogs, Italian life insurer <strong>Eurovita<\/strong>\u2019s collapse in 2023 looms large.<\/p>\n<p>Eurovita went into administration as interest rates rose, and its private equity backer failed to put in all the extra capital that regulators wanted. Policyholders rushed for the exits.<\/p>\n<p>Last year, Apollo chief <strong>Marc Rowan<\/strong> complained that acquisitions were proving \u201cpolitically very difficult\u201d in Europe and some jurisdictions had been \u201chostile to private markets\u201d.<\/p>\n<p>That Athora, minority owned by Apollo, is buying PIC instead of its wholly owned US insure <strong>Athene<\/strong> is an interesting quirk of the deal.<\/p>\n<p>Apollo owns only a quarter of Athora, with its large investors and management owning the remainder, meaning the private capital group will forgo the full insurance spread it retains through deals with Athene. Instead, it would collect a fee for managing some \u2014 though not all \u2014 of PIC\u2019s assets.<\/p>\n<p>Athora is presenting itself as a long-term strategic owner of PIC, versus the private equity backers <strong>Reinet Investments<\/strong> and <strong>CVC<\/strong> that are selling the insurer.\u00a0\u00a0<\/p>\n<p>\u201cThe most common question I get is: \u2018Do you have private equity fund capital?\u2019 We have none,\u201d said Athora chief executive <strong>Mike<\/strong> <strong>Wells<\/strong>.<\/p>\n<p>Merck courts Verona, reviving Big Pharma\u2019s M&amp;A love affair<\/p>\n<p>Pharma giants are fast approaching patent cliffs and they\u2019re returning to a tried and tested strategy to keep them falling off the brink: buying biotechs with promising drugs.<\/p>\n<p><strong>Merck<\/strong>\u2019s <a href=\"https:\/\/www.ft.com\/content\/bf1c2253-15b3-426a-975d-15ddca1d84a5\" data-trackable=\"link\" target=\"_blank\" rel=\"noopener\">$10bn deal<\/a> for <strong>Verona Pharma<\/strong>, scooped by DD\u2019s Oliver Barnes on Wednesday, is a case in point.\u00a0<\/p>\n<p>Verona holds the patent for <strong>Ohtuvayre<\/strong>, a drug to treat chronic obstructive pulmonary disease that\u2019s already been approved in the US.<\/p>\n<p>Ohtuvayre could plug a revenue hole when Merck\u2019s trophy product, <strong>Keytruda<\/strong>, comes off patent in 2028.<\/p>\n<p>Keytruda is the world\u2019s bestselling drug, raking in $30bn every year. But once the patent expires, rivals will be able to sell the drug on the cheap, decimating Merck\u2019s sales.<\/p>\n<p>So it\u2019s no wonder that Merck splashed the cash to get a hold of Ohtuvayre: the Verona Pharma deal is the second biggest in biotech this year and Merck\u2019s biggest takeover in two years.<\/p>\n<p>(The deal is also a huge coup for Merck\u2019s legal adviser, <strong>Freshfields<\/strong>. The <a href=\"https:\/\/www.ft.com\/content\/1d56ce76-14b4-422f-a75b-f8b041624cba\" data-trackable=\"link\" target=\"_blank\" rel=\"noopener\">London-based Magic Circle firm<\/a> rarely advises on big US acquisitions.)<\/p>\n<p>It all comes at a trying time for Big Pharma, which is contending with the threat of sectoral tariffs from US President Donald Trump and the looming spectre of competitors from China.<\/p>\n<p>And in 2027 and 2028, an <a href=\"https:\/\/www.ft.com\/content\/360cb65b-a9ab-4fed-b8b3-7c34f2560938\" data-trackable=\"link\" target=\"_blank\" rel=\"noopener\">alarming $180bn of drugs will go off patent<\/a>, leaving Merck and other pharma giants such as <strong>Bristol Myers Squibb<\/strong> and <strong>Pfizer<\/strong> with a shortfall to fill.\u00a0<\/p>\n<p>The revenue gap could be existential for the industry if it doesn\u2019t act soon. <\/p>\n<p>Fortunately for drugmakers, they\u2019re sitting on $1.3tn of dry powder. In a fallow year for mergers and acquisitions, that\u2019s giving dealmakers hope that a biopharma M&amp;A boom could be on the horizon.<\/p>\n<p><strong>Nasdaq<\/strong>\u2019s biotech index was up nearly 3 per cent on Wednesday in the wake of Merck\u2019s acquisition, a sure sign that investors foresee a flurry of deals in the sector.<\/p>\n<p>Trouble in paradise for Jane Street in India<\/p>\n<p>A week ago lots of people at New York trading powerhouse <strong>Jane Street<\/strong> were probably eagerly awaiting a long, warm and barbecue-filled July 4 weekend. By the end of it they were shell-shocked.<\/p>\n<p>On the eve of Independence Day in the US, India\u2019s financial regulator abruptly slapped Jane Street with accusations of \u201csinister\u201d market manipulation and banned the proprietary trading firm from the country until it stumps up about $550mn of \u201cillegal gains\u201d that it says it has found so far.\u00a0<\/p>\n<p>The scandal has cast a <a href=\"https:\/\/www.ft.com\/content\/6789512f-8775-450b-b0a6-9d9d0c3716ca\" data-trackable=\"link\" target=\"_blank\" rel=\"noopener\">pall over Jane Street<\/a>, which until now seemed like it could do no wrong.<\/p>\n<p>Last year it made more than $20bn of net trading revenues, and in the first quarter of 2025 alone it made $7.2bn, more than <strong>Morgan Stanley<\/strong>\u2019s traders. Even its <a href=\"https:\/\/www.ft.com\/content\/216eb75a-f856-496d-8e02-c8cb73269548\" data-trackable=\"link\" target=\"_blank\" rel=\"noopener\">interns earn more<\/a> than <strong>Federal Reserve<\/strong> chair <strong>Jay Powell<\/strong>.<\/p>\n<p>Now, the FT reports that the interim order from the <strong>Securities and Exchange Board of India<\/strong> could prove to be just the beginning of its troubles.\u00a0<\/p>\n<p>For more details on precisely what Jane Street is alleged to have done in India, our friends at Alphaville have <a href=\"https:\/\/www.ft.com\/content\/41c4789a-afa6-462c-a6ea-9704c2ba78a7\" data-trackable=\"link\" target=\"_blank\" rel=\"noopener\">zoomed in<\/a> on what appears to be the crux of the issue: heavy trading in India\u2019s wildly engorged options market.<\/p>\n<p>(Alphaville also had an attempt at \u201c<a href=\"https:\/\/www.ft.com\/content\/961071df-cd2c-46c5-8449-c8aa097c35ef\" data-trackable=\"link\" target=\"_blank\" rel=\"noopener\">steel-manning<\/a>\u201d Jane Street\u2019s defence.)\u00a0<\/p>\n<p>Jane Street strongly disputes the allegations. In an <a href=\"https:\/\/www.ft.com\/content\/6cf91467-4dd6-4dd7-97c6-c30a6a1f7afe\" data-trackable=\"link\" target=\"_blank\" rel=\"noopener\">internal email seen by the FT<\/a>, it told its more than 3,000 employees that it was \u201cpainful to have our firm\u2019s reputation tarnished by a report based on so many erroneous or unsupported assertions\u201d and promised to fight the charges.<\/p>\n<p>However, many rivals both <a href=\"https:\/\/www.linkedin.com\/posts\/gerko_here-is-my-view-on-jane-street-story-based-activity-7347200203814305792-ycIW\/?utm_source=share&amp;utm_medium=member_desktop&amp;rcm=ACoAAAShISUBd2tZUTMC6K9zSfN6-EnIyv7CHV4\" data-trackable=\"link\" target=\"_blank\" rel=\"noopener\">publicly<\/a> and privately said the Indian regulator\u2019s report reflected poorly on Jane Street.<\/p>\n<p>\u201cSometimes you read a regulator\u2019s complaint and think they just don\u2019t get what\u2019s going on,\u201d an executive at a competitor told DD. \u201cBut in this case Sebi laid out a strong case.\u201d<\/p>\n<p>Job moves<\/p>\n<ul class=\"o3-editorial-typography-list-unordered\">\n<li>\n<p><strong>X<\/strong>\u2019s <strong>Linda Yaccarino <\/strong>said she would <a href=\"https:\/\/www.ft.com\/content\/12c69972-4f27-4050-8e1c-1cb84646b9b2\" data-trackable=\"link\" target=\"_blank\" rel=\"noopener\">step down<\/a> as chief executive of the social media platform owned by <strong>Elon Musk <\/strong>after two years at the helm.\u00a0<\/p>\n<\/li>\n<li>\n<p><strong>Apple <\/strong>has named <strong>Sabih Khan<\/strong> as its chief operating officer. Khan joined Apple in 1995 and <a href=\"https:\/\/www.ft.com\/content\/bb76f133-0e47-4aa3-a018-dfd6a22dea56\" data-trackable=\"link\" target=\"_blank\" rel=\"noopener\">succeeds his current boss<\/a> <strong>Jeff Williams<\/strong>, who will retire later this year. <strong>Tim Cook<\/strong> held the role before he was appointed chief executive.<\/p>\n<\/li>\n<li>\n<p><strong>EG Group<\/strong> has named <strong>Mark Segal<\/strong> as its finance chief. He was most recently at <strong>Spin Master<\/strong>, where he was CFO.<\/p>\n<\/li>\n<li>\n<p><strong>Lazard<\/strong> has appointed <strong>Jon Steinberg<\/strong> as a managing director in its media, entertainment and sports advisory group. He was most recently chief executive of <strong>Future Plc<\/strong> and founded <strong>Cheddar News<\/strong>.<\/p>\n<\/li>\n<li>\n<p><strong>King Street <\/strong>has hired <strong>Philip Brown<\/strong> as a managing director on its US research team. He joins from <strong>P. Schoenfeld Asset Management<\/strong>, where he was a partner.<\/p>\n<\/li>\n<\/ul>\n<p>Smart reads<\/p>\n<p><strong>Digital renminbi <\/strong>The US dollar remains the currency of choice for stablecoins. But in mainland China, where cryptocurrencies are banned, local policymakers are <a href=\"https:\/\/www.ft.com\/content\/a1774773-0ef9-4437-a18d-fa4012d9e458\" data-trackable=\"link\" target=\"_blank\" rel=\"noopener\">starting to take interest<\/a>, Lex writes.<\/p>\n<p><strong>Dogefight <\/strong>Elon Musk may be gone from the so-called Department of Government Efficiency, but his allies remain, the Wall Street Journal writes. And they\u2019re <a href=\"https:\/\/www.wsj.com\/politics\/policy\/doge-elon-musk-left-control-92770407\" data-trackable=\"link\" target=\"_blank\" rel=\"noopener\">sparring with the White House<\/a> for control.<\/p>\n<p><strong>Crypto lobbyists<\/strong> Trump\u2019s <a href=\"https:\/\/www.nytimes.com\/2025\/07\/09\/us\/politics\/trump-crypto-lobbying.html\" data-trackable=\"link\" target=\"_blank\" rel=\"noopener\">Damascene conversion<\/a> to crypto cheerleader followed \u201cone of the great lobbying free-for-alls in recent history\u201d, the New York Times writes, in a behind-the-scenes dissection of his transformation.<\/p>\n<p>News round-up<\/p>\n<p><a href=\"https:\/\/www.ft.com\/content\/23e2518b-db26-4091-888e-01438f3c89eb\" data-trackable=\"link\" target=\"_blank\" rel=\"noopener\">Nvidia becomes first company to reach $4tn in market value<\/a> (FT)<\/p>\n<p><a href=\"https:\/\/www.ft.com\/content\/2c4c6957-f858-483a-984b-6a009b454e94\" data-trackable=\"link\" target=\"_blank\" rel=\"noopener\">BCG\u2019s role in Gaza probed by UK parliamentary committee<\/a> (FT)<\/p>\n<p><a href=\"https:\/\/www.bloomberg.com\/news\/articles\/2025-07-09\/goldman-asks-junior-bankers-to-swear-they-haven-t-landed-private-equity-jobs\" data-trackable=\"link\" target=\"_blank\" rel=\"noopener\">Goldman demands oath from junior bankers to fend off private equity<\/a> (Bloomberg)<\/p>\n<p><a href=\"https:\/\/www.ft.com\/content\/34db0347-52d9-4cf8-a811-29f502217fd1\" data-trackable=\"link\" target=\"_blank\" rel=\"noopener\">Italian candy maker Ferrero in talks for storied US cereal maker Kellogg\u2019s<\/a> (FT)<\/p>\n<p><a href=\"https:\/\/www.ft.com\/content\/b814a406-fe61-41f4-8a48-e4a1b31948ce\" data-trackable=\"link\" target=\"_blank\" rel=\"noopener\">Singapore\u2019s Temasek sours on European companies amid US tariff threats<\/a> (FT)<\/p>\n<p><a href=\"https:\/\/www.ft.com\/content\/b5d7caa9-7ae1-4de7-bc3c-8ad68d1ed556\" data-trackable=\"link\" target=\"_blank\" rel=\"noopener\">Hedge funds to blame for coffee price surge, says Lavazza boss<\/a> (FT)<\/p>\n<p><a href=\"https:\/\/www.ft.com\/content\/ef6bbb12-1ef5-4fc7-bff5-77d000c36bff\" data-trackable=\"link\" target=\"_blank\" rel=\"noopener\">Apple bids for Formula 1 rights in US after success of Brad Pitt film<\/a> (FT)<\/p>\n<p><a href=\"https:\/\/www.ft.com\/content\/f84f1e9c-6664-45ee-bc36-4d6d130cf99a\" data-trackable=\"link\" target=\"_blank\" rel=\"noopener\">Blackstone-owned casino operator Cirsa rises on market debut<\/a> (FT)<\/p>\n<p><a href=\"https:\/\/www.ft.com\/content\/c6bcc03a-972e-4d9d-8fc7-03e5a18de619\" data-trackable=\"link\" target=\"_blank\" rel=\"noopener\">Top financial watchdog recommends limits on hedge fund leverage<\/a> (FT)<\/p>\n<p><a href=\"https:\/\/www.ft.com\/content\/fc019bc9-133a-4627-9849-acc02336d6cf\" data-trackable=\"link\" target=\"_blank\" rel=\"noopener\">Thames Water refuses to claw back bonuses despite government threats<\/a> (FT)<\/p>\n<p>Due Diligence is written by <a href=\"https:\/\/www.ft.com\/arash-massoudi\" data-trackable=\"link\" target=\"_blank\" rel=\"noopener\">Arash Massoudi<\/a>, <a href=\"https:\/\/www.ft.com\/ivan-levingston\" data-trackable=\"link\" target=\"_blank\" rel=\"noopener\">Ivan Levingston<\/a>, <a href=\"https:\/\/www.ft.com\/ortenca-aliaj\" data-trackable=\"link\" target=\"_blank\" rel=\"noopener\">Ortenca Aliaj<\/a>, <a href=\"https:\/\/www.ft.com\/alexandra-heal\" data-trackable=\"link\" target=\"_blank\" rel=\"noopener\">Alexandra Heal<\/a> and <a href=\"https:\/\/www.ft.com\/robert-smith\" data-trackable=\"link\" target=\"_blank\" rel=\"noopener\">Robert Smith<\/a> in London, <a href=\"https:\/\/www.ft.com\/james-fontanella-khan\" data-trackable=\"link\" target=\"_blank\" rel=\"noopener\">James Fontanella-Khan<\/a>, <a href=\"https:\/\/www.ft.com\/sujeet-indap\" data-trackable=\"link\" target=\"_blank\" rel=\"noopener\">Sujeet Indap<\/a>, <a href=\"https:\/\/www.ft.com\/eric-platt\" data-trackable=\"link\" target=\"_blank\" rel=\"noopener\">Eric Platt<\/a>, <a href=\"https:\/\/www.ft.com\/antoine-gara\" data-trackable=\"link\" target=\"_blank\" rel=\"noopener\">Antoine Gara<\/a>, <a href=\"https:\/\/www.ft.com\/amelia-pollard\" data-trackable=\"link\" target=\"_blank\" rel=\"noopener\">Amelia Pollard<\/a>, <a href=\"https:\/\/www.ft.com\/maria-heeter\" data-trackable=\"link\" target=\"_blank\" rel=\"noopener\">Maria Heeter<\/a>, <a href=\"https:\/\/www.ft.com\/kaye-wiggins\" data-trackable=\"link\" target=\"_blank\" rel=\"noopener\">Kaye Wiggins<\/a>, <a href=\"https:\/\/www.ft.com\/oliver-barnes\" data-trackable=\"link\" target=\"_blank\" rel=\"noopener\">Oliver Barnes<\/a>, <a href=\"https:\/\/www.ft.com\/jamie-john\" data-trackable=\"link\" target=\"_blank\" rel=\"noopener\">Jamie John<\/a> and Hannah Pedone in New York, <a href=\"https:\/\/www.ft.com\/george-hammond\" data-trackable=\"link\" target=\"_blank\" rel=\"noopener\">George Hammond<\/a> and <a href=\"https:\/\/www.ft.com\/tabby-kinder\" data-trackable=\"link\" target=\"_blank\" rel=\"noopener\">Tabby Kinder<\/a> in San Francisco, <a href=\"https:\/\/www.ft.com\/arjun-neil-alim\" data-trackable=\"link\" target=\"_blank\" rel=\"noopener\">Arjun Neil Alim<\/a> in Hong Kong. Please send feedback to <a href=\"https:\/\/www.ft.com\/content\/mailto:%20due.diligence@ft.com\" data-trackable=\"link\" target=\"_blank\" rel=\"noopener\">due.diligence@ft.com<\/a><\/p>\n<p>Recommended newsletters for you<\/p>\n<p><strong>India Business Briefing<\/strong> \u2014 The Indian professional\u2019s must-read on business and policy in the world\u2019s fastest-growing large economy. Sign up <a href=\"https:\/\/ep.ft.com\/newsletters\/subscribe?newsletterIds=6745dd55d6c53004ca71b49d\" data-trackable=\"link\" target=\"_blank\" rel=\"noopener\">here<\/a><\/p>\n<p><strong>Unhedged<\/strong> \u2014 Robert Armstrong dissects the most important market trends and discusses how Wall Street\u2019s best minds respond to them. Sign up <a href=\"https:\/\/ep.ft.com\/newsletters\/subscribe?newsletterIds=584573e552860d000491cdb8\" data-trackable=\"link\" target=\"_blank\" rel=\"noopener\">here<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"One scoop to start: Revolut is in talks to raise new funding from investors at a $65bn valuation&hellip;\n","protected":false},"author":2,"featured_media":252710,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5018,3,4],"tags":[748,393,4884,1144,712,16,15,1764],"class_list":{"0":"post-252709","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-britain","8":"category-uk","9":"category-united-kingdom","10":"tag-britain","11":"tag-england","12":"tag-great-britain","13":"tag-northern-ireland","14":"tag-scotland","15":"tag-uk","16":"tag-united-kingdom","17":"tag-wales"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@uk\/114827384794292848","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/252709","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/comments?post=252709"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/252709\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media\/252710"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media?parent=252709"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/categories?post=252709"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/tags?post=252709"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}